

Vivinex™

MODEL **XC1-SP** | MODEL **XY1-SP**

Vivinex™ multiSert™

OSTROŚĆ WIDZENIA, BEZPIECZEŃSTWO APLIKACJI.



NIESPOTYKANA OSTROŚĆ WIDZENIA


- **Akryl hydrofobowy** gwarantujący brak olśnień^{1,2}
- **Oryginalna asferyczna konstrukcja optyki** zapewniająca lepszą jakość obrazu³
- **Obróbka aktywnym tlenem, gładka powierzchnia** oraz **ostra krawędź redukujące PCO**^{2,4,5,6,7,8,9,10}

BEZPIECZEŃSTWO I PEŁNA KONTROLA APLIKACJI

- **System tłokowy obsługiwany jedną dłońią oraz wkręcany, obsługiwany oburącz, dostępny** w jednym urządzeniu
- **Unikatowa, ruchoma osłona tipa**, przeznaczona do kontroli głębokości aplikacji
- **System multiSert™** gwarantuje **wyjątkową stabilność i powtarzalność wszczepu**¹¹

Vivinex™

MODEL XC1-SP | MODEL XY1-SP



multiSert™




Vivinex™ multiSert™	
Nazwa modelu	XC1-SP XY1-SP
Optyka	Asferyczna z ostrą, teksturowaną krawędzią optyki
Materiał optyki i haptenów	Akryl hydrofobowy Vivinex™ z filtrem UV (Model XC1-SP), z filtrem światła niebieskiego (Model XY1-SP)
Budowa haptenów	Teksturowane, szorstkie, odwrócone C-loop
Wymiary	6.00 mm / 13.00 mm
Moc	+6.00 do +30.00 D (krok co 0.50 D)
Skala A nominalna*	118.9
Zoptymalizowane stałe**	Haigis $a_0 = -0.8733$ $a_1 = 0.2093$ $a_2 = 0.2277$
	Hoffer Q pACD = 5.693
	Holladay 1 sf = 1.926
	SRK/T A = 119.18
Injector	multiSert™ preloaded
Średnica zew. tipa injektora	1.70 mm
Rekomendowane cięcia	2.20 mm


System multiSert™ 4 w 1 gwarantuje wyjątkową kontrolę aplikacji oraz umożliwia wybór sposobu implantacji

Jednoręczny

Dwuręczny



System tłokowy



System wkręcany

Aplikacja do torby soczewki

Aplikacja pod tunel cięcia



Ostoną w pozycji wyjściowej



Ostoną w pozycji aktywnej

* The A-constant is presented as a starting point for the lens power calculation. When calculating the exact lens power, it is recommended that calculations be performed individually, based on the equipment used and operating surgeon's own experience.
 ** These optimized constants for the calculation of intraocular lens power published by IOLCon on their website: <https://iolcon.org> are calculated from 1,444 clinical results for Vivinex™ model XY1/XC1 as of January 11, 2021. These constants are based on actual surgical data and are provided by IOLCon as a starting point for individual constant optimizations. The information available on the website is based on data originating from other users and not by HOYA Surgical Optics ("HSO"). HSO therefore does not warrant the correctness, completeness and currentness of the contents on the said website.

1 Glistening-free per Miyata scale; study result of the The David J Apple International Laboratory for Ocular Pathology, University Hospital Heidelberg. Report on file.
 2 HOYA data on file. DoF-CTM-21-002, HOYA Medical Singapore Pte. Ltd, 2021
 3 Pérez-Merino, P.; Marcos, S. (2018): Effect of intraocular lens decentration on image quality tested in a custom model eye. In: Journal of cataract and refractive surgery 44 (7), p. 889-896.
 4 Leydolt, C. et al. (2020): Posterior capsule opacification with two hydrophobic acrylic intraocular lenses: 3-year results of a randomized trial. In: American journal of ophthalmology 217 (9), p. 224-231.
 5 Giacinto, C. et al. (2019): Surface properties of commercially available hydrophobic acrylic intraocular lenses: Comparative study. In: Journal of cataract and refractive surgery 45 (9), p. 1330-1334.
 6 Werner, L. et al. (2019): Evaluation of clarity characteristics in a new hydrophobic acrylic IOL in comparison to commercially available IOLs. In: Journal of cataract and refractive surgery 45 (10), p. 1490-1497.
 7 Matsushima, H. et al. (2006): Active oxygen processing for acrylic intraocular lenses to prevent posterior capsule opacification. In: Journal of cataract and refractive surgery 32 (6), p. 1035-1040.
 8 Farukhi, A. et al. (2015): Evaluation of uveal and capsule biocompatibility of a single-piece hydrophobic acrylic intraocular lens with ultraviolet-ozone treatment on the posterior surface. In: Journal of cataract and refractive surgery 41 (5), p. 1081-1087.
 9 Eldred, J. et al. (2019): An In Vitro Human Lens Capsular Bag Model Adopting a Graded Culture Regime to Assess Putative Impact of IOLs on PCO Formation. In: Investigative ophthalmology & visual science 60 (1), p. 113-122.
 10 Nanavaty, M. et al. (2019): Edge profile of commercially available square-edged intraocular lenses: Part 2. In: Journal of cataract and refractive surgery 45 (6), p. 847-853.
 11 Usability and acceptability evaluation of the multiSert™ injector system, HOYA data on file DoF-SERT-102-MULT-03052018 (2018).

Information contained is intended for health care professionals. For a full list of indications and contra indications please refer to the Instructions For Use. Some of the products and/or specific features as well as the procedures featured in this document may not be approved in your country and thus may not be available there. Design and specifications are subject to change without prior notice as a result of ongoing technical development. Please contact our regional representative regarding individual availability in your country. HOYA, Vivinex and multiSert are trademarks of the HOYA Corporation or its affiliates. ©2021 HOYA Medical Singapore Pte. Ltd. All rights reserved.

HOYA Medical Singapore Pte. Ltd | 455A Jalan Ahmad Ibrahim | Singapore 639939

HOYA Surgical Optics GmbH | De-Saint-Exupéry-Straße 10 | 60549 Frankfurt am Main | Germany
 Hotline DE: Tel. +49 (0)800 664 2 664 | Fax +49 (0)800 774 2 774

hoyasurgicaloptics.com

0123

www.consultronix.pl

2021-06-21_HSOE_XC1-SP_XY1-SP_DS_EN